Facebook
Twitter
LinkedIn
Forward
Virtual Symposium - Assessing the Evolving Role of GLP1-RAs to Reduce Cardiovascular Risk: Emerging Evidence, Evolving Guidance, and Expert Perspectives
GLP-1 RAs have carved an important role in the management of patients with type 2 diabetes (T2D), not only in glycemic control, but also in reducing cardiovascular and renal risk. The evolving evidence with GLP-1 RA in this setting has led to important studies and guideline changes, all with significant implications for patient management. Given the breadth of the evidence, it might be challenging to interpret these advances, and during this symposium, held during the 17th Annual Cardiometabolic Health meeting, our experts discuss how this new evidence impacts the individualization of therapy for T2D patients.
Target Audience
US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
Learning Objectives
After completing this activity, the participant should be better able to:
- Discuss the mechanisms of action and different properties of GLP-1 RAs.
- Summarize the efficacy and safety of GLP-1 RAs, alone or in combination, for the management of T2DM.
- Review the current evidence from CVOTs and real-world studies with GLP-1 RAs and their practice implications in managing T2DM patients with CVD or at CVD risk.
- List recent guideline updates about the individualization of T2DM therapy in patients with existing CVD or CVD risk.
- Select individualized treatment strategies for patients with T2DM that optimize glycemic control and reduce overall CVD risk.
Additional Information
| Attachment | Size |
|---|---|
 Symposium Transcript | 207.54 KB |
Chair
Vanita R. Aroda, MD
Director, Diabetes Clinical Research, Brigham and Women’s Hospital
Boston, MA
Dr. Aroda discloses the following:
Consultant, Advisor, Speaker: Applied Therapeutics, Fractyl, Novo Nordisk, Pfizer, Sanofi
Researcher: Applied Therapeutics, Eli Lilly, Premier/Fractyl, Novo Nordisk, Sanofi
Faculty
Marie E. McDonnell, MD
Chief of Diabetes Section and Director of the Diabetes Program, Brigham & Women's Hospital
Boston, MA
Dr. McDonnell discloses the following:
Other: Eli-Lilly
Consultant, Advisor, Speaker: Everlywell, Inc
Jorge Plutzky, MD
Director, Preventive Cardiology, Brigham and Women's Hospital
Boston, MA
Dr. Plutzky has no relevant financial relationship(s) with ineligible companies to disclose.
ESTIMATED TIME TO COMPLETE ACTIVITY
1 hour
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Novo Nordisk.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 1 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-23-016-H01-P. Type of activity: Application
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DIETITIAN CONTINUING EDUCATION
This program offers 1.0 CPEUs for dietitians.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. During the period January 18, 2023 through January 18, 2024, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For additional information about the accreditation of this activity, please visit https://partnersed.com
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
DISCLOSURES
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF CONFLICT OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.00 ABIM MOC and AMA PRA Category 1 Credit™
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.